Introduction
Melanoma is the most aggressive form of skin cancer, characterized by high metastatic potential and a significant mortality rate. While surgical excision is the standard primary treatment, it often fails to eliminate all malignant cells, leading to local recurrence. Conventional systemic chemotherapy faces two major hurdles: significant off-target toxicity and the poor physicochemical properties of many potent compounds. For instance, the ginger-derived sesquiterpenoid Zerumbone (ZER) is poorly water-soluble, while the photothermal agent Indocyanine Green (ICG) is prone to rapid degradation and aggregation. To overcome these barriers, researchers have developed a transdermal delivery platform designed to deliver these agents directly into the tumor microenvironment.
System Design and Methodology
The researchers developed a multi-stage delivery system that combines nanotechnology with microneedle engineering to ensure localized, synergistic therapy.
As illustrated in the figure above, the process begins with the encapsulation of ZER and ICG within self-assembling mPEG-PLA polymeric micelles. This nanocarrier approach solves the solubility issues of ZER and stabilizes ICG. These micelles are then loaded into the tips of pyramid-shaped dissolvable microneedles (DMNs) made of Hyaluronic Acid (HA). These needles, approximately 507 µm in height, are designed to penetrate the skin's outer barrier (the stratum corneum) to a depth of ~280 µm. Once inserted, the HA matrix dissolves within five minutes, releasing the therapeutic payload directly at the tumor site.
Synergistic Therapeutic Mechanism
The system utilizes a triple-threat mechanism triggered by an 808 nm Near-Infrared (NIR) laser:
- Chemotherapy: ZER induces apoptosis (programmed cell death) by disrupting mitochondrial membrane potential.
- Photothermal Therapy (PTT): Upon NIR irradiation, ICG converts light into localized heat (reaching ~56°C), effectively "cooking" the cancer cells.
- Photodynamic Therapy (PDT): The NIR trigger also causes ICG to produce Reactive Oxygen Species (ROS), which further damage the tumor cells.
Key Results and Insights
The study utilized B16F10 and A375 melanoma cell lines for in vitro testing and BALB/c nude mice for in vivo efficacy and safety assessments.
- Unprecedented Tumor Inhibition: The combination of ZER-ICG@DMNs and NIR laser treatment achieved a 99.35% Tumor Inhibition Rate (IRT). In the combination group, 3 out of 5 mice showed complete tumor ablation.
- Mitochondrial Targeting: The ZER-ICG micelles were shown to specifically accumulate in the mitochondria, triggering the intrinsic pathway of cell suicide.
- Superior Safety Profile: Unlike systemic chemotherapy, this localized approach showed no damage to major organs (heart, liver, spleen, lungs, and kidneys) via H&E staining. Blood biochemical markers (ALT, AST, BUN) remained within normal ranges, confirming minimal systemic toxicity.
- Immune Modulation: The treatment also led to a downregulation of F4/80, suggesting a potential reduction in pro-tumor M2 macrophages within the tumor microenvironment.
Conclusion and Future Outlook
The ZER-ICG@DMN patch offers a highly effective, localized, and minimally invasive strategy for treating superficial malignant tumors. By bypassing systemic circulation, the system maximizes therapeutic impact while virtually eliminating side effects. Future work will focus on optimizing the system for sustained drug release and exploring methods to apply this NIR-triggered technology to deeper-seated malignancies.
Summary updated